Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Net reclassification improvement with serial biomarkers and bed-sided spirometry to early predict the need of organ support during the early post-transplantation in-hospital stay in allogeneic HCT recipients

Abstract

To predict the need of intensive care unit admission with organ support during the transplantation hospital stay in 101 consecutives allogeneic hematopoietic cell transplantation (allo-HCT) recipients the added predictive utility of three times per week Copeptin, MR-proADM, MR-proANP, NT-proBNP, IL-6, Procalcitonin, d-dimer and three times per week bed-sided pulmonary function test was determined in comparison with an index model. The index model was calculated by multivariate regression analysis out of the patients’ routine laboratory parameters. To calculate the added predictive utility of the investigated markers the Δ-AUC and the continuous net reclassification improvement (cNRI + 2 to − 2), splitted for events and non-events were calculated for each marker in comparison with the index model. According to the Δ-AUC, none of the parameters improved risk prediction. In contrast, the cNRI was significantly improved for events and non-events by Copeptin (event 0.75, p value 0.0013; non-event 0.4, p value 0.000079) and for events by NT-proBNP (0.6, p value 0.018). d-dimer and PCT significantly predicted the non-event. Of the spirometry parameters, the FEF50% improved prediction of event and non-event according to the cNRI model. Our data support the additional serial analysis of Copeptin and NT-proBNP in allo-HCT recipients during the transplantation hospital stay.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Afessa B, Peters SG. Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med. 2006;27:297–309.

    Article  PubMed  Google Scholar 

  2. Afessa B, Azoulay E. Critical care of the hematopoetic stem cell transplant recipient. Crit Care Clin. 2010;26:133–50.

    Article  CAS  PubMed  Google Scholar 

  3. Benz R, Schanz U, Maggiorini M, Seebach JD, Stussi G. Risk factors for ICU admission and ICU survival after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49:62–65.

    Article  CAS  PubMed  Google Scholar 

  4. Kew A, Couban S, Patrick W, Thompsen K, White D. Outcome of hematopoetic stem cell transplant recipients admitted to the intensive care unit. Biol Blood Marrow Transplant. 2006;12:301–5.

    Article  PubMed  Google Scholar 

  5. Orvain C, Beloncle F, Hamel JF, Thepot S, Mercier M, Kouatchet A, et al. Different impact of the number of organ failures and graft-versus-host disease on the outcome of allogeneic stem cell transplantation recipients requiring intensive care. Transplantation. 2017;101:437–44.

    Article  PubMed  Google Scholar 

  6. Lengline E, Chevret S, Moreau AS, Pene F, Blot F, Bourhis JH. Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015;50:840–5.

    Article  CAS  PubMed  Google Scholar 

  7. Bönig H,Schneider D,Sprock I,Lemburg P,Göbel U,Nürnberger W, ‘Sepsis’ and multi-organ failure: predictors of poor outcome after hematopoietic stem cell transplantation in children. Bone Marrow Transplant. 2000;25:S32–34.

    Article  PubMed  Google Scholar 

  8. Boyaci N, Aygencel G, Turkoglu M, Yegin Z, Acar K, Sucak GT. The intensive care management process in patients with hematopoietic stem cell transplantation and factors affecting their prognosis. Hematology. 2014;19:338–45.

    Article  PubMed  Google Scholar 

  9. Kroschinsky F, Weise M, Illmer T, Haenel M, Bornhäuser M, Höffken G. Outcome and prognostic features of intensive care unit treatment in patients with hematological malignancies. Intensive Care Med. 2002;28:1294–1300.

    Article  PubMed  Google Scholar 

  10. Ho VT, Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:223–9.

    Article  CAS  PubMed  Google Scholar 

  11. Sharma S, Nadrous HF, Peters SG, Tefferi A, Litzow MR, Aubry MC. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest. 2005;128:1385–92.

    Article  PubMed  Google Scholar 

  12. Lucena CM, Torres A, Rovira M, Marcos M, de la Bellacasa J, Sanchez M. Pulmonary complications in hematopoietic SCT: a prospective study. Bone Marrow Transplant. 2014;49:1293–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Agusti C, Ramirez J, Picado C, Xaubet A, Carreras E, Ballester E. Diffuse alveolar hemorrhage in allogeneic bone marrow transplantation. A post-mortem study. Am J Respir Crit Care Med. 1995;151:1006–10.

    CAS  PubMed  Google Scholar 

  14. Majhail NS, Parks K, Defor TE, Weisdorf DJ. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant. 2006;12:1038–46.

    Article  PubMed  Google Scholar 

  15. Heggen J, West C, Olson T, Teague G, Fortenberry J, Yeager AM. Diffuse alveolar hemorrhage in pediatric hematopoietic cell transplant patients. Pediatrics. 2002;109:965–71.

    Article  PubMed  Google Scholar 

  16. Armenian SH, Ryan TD, Khouri MG. Cardiac dysfunction and heart failure in hematopoietic cell transplanation survivors: emerging paradigms in pathophysiology, screening, and prevention. Heart Fail Clin. 2017;13:337–45.

    Article  PubMed  Google Scholar 

  17. Lin CJ, Vader JM, Slade M, DiPersio JF, Westervelt P, Romee R. Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation. Cancer. 2017;123:1800–9.

    Article  CAS  PubMed  Google Scholar 

  18. Naeem N, Reed MD, Creger RJ, Youngner SJ, Lazarus HM. Transfer of the hematopoetic stem cell transplant patient to the intensive care unit: does it really matter? Bone Marrow Transplant. 2006;37:119–33.

    Article  CAS  PubMed  Google Scholar 

  19. Saillard C, Blaise D, Mokart D. Critical ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis. Bone Marrow Transplant. 2016;51:1050–61.

    Article  CAS  PubMed  Google Scholar 

  20. Platon L, Amigues L, Ceballos P, Fegueux N, Daubin D, Besnard N, et al. A reappraisal of ICU and long-term outcome of allogeneic hematopietic stem cell transplantation patients and reassessment of prognosis factors: results of a 5-year cohort study (2009-2013). Bone Marrow Transplant. 2016;51:256–61.

    Article  CAS  PubMed  Google Scholar 

  21. Azoulay E, Pene F, Darmon M, Lengline F, Benoit D, Soares M, et al. Managing critical ill hematology patients: time to think differently. Blood Rev. 2015;29:359–67.

    Article  PubMed  Google Scholar 

  22. Shorr A, Kollef M. The quick and the dead: the importance of rapid evaluation in infiltrates in the immunocompromised patient. Chest. 2002;122:9–12.

    Article  PubMed  Google Scholar 

  23. Bokhari S, Munir T, Memon S, Byrne J, Russell N, Beed M. Impact of critical care reconfiguration and track-and-trigger outreach team intervention on outcomes of haematology patients requiring intensive care admission. Ann Hematol. 2010;89:505–12.

    Article  PubMed  Google Scholar 

  24. Paczesny S, Diaz-Ricart M, Carreras E, Cooke K. Translational research efforts in biomarkers and biology of early transplant-related complications. Biol Blood Marrow Transplant. 2011;17:S101–S108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Paczesny S. Biomarkers for fatal immune response to stem cell treatment could reduce mortality. Biomark Med. 2014;8:65–68.

    Article  CAS  PubMed  Google Scholar 

  26. Massaro KS, Macedo R, deCastro BS, Dulley F, Oliveira MS, Yasuda MA, et al. Risk factor for death in hematopoietic stem cell transplantation: are biomarkers useful to foresee the prognosis in this population of patients? Infection. 2014;42:1023–32.

    Article  CAS  PubMed  Google Scholar 

  27. Sormani MP, Oneto R, Bruno B, Fiorone M, Lamparelli T, Gualandi F, et al. A revised day + 7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose. Bone Marrow Transplant. 2003;32:205–11.

    Article  CAS  PubMed  Google Scholar 

  28. Wang XS, Shi Q, Williams LA, Cleeland CS, Mobley GM, Reuben JM, et al. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer. 2008;113:2102–9.

    Article  PubMed  Google Scholar 

  29. DiCarlo J, Agarwal-Hashmi R, Shah A, Kim P, Craveiro L, Killen R, et al. Cytokine and chemokine patterns across 100 days after hematopoetic stem cell transplantation in children. Biol Blood Marrow Transplant. 2014;20:361–9.

    Article  CAS  PubMed  Google Scholar 

  30. Zhao X, Boenisch O, Yeung M, Mfarrej B, Yang S, Turka LA, et al. Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance. Am J Transplant. 2012;12:90–101.

    Article  CAS  PubMed  Google Scholar 

  31. Pihusch M, Pihusch R, Fraunberger P, Pihusch V, Andreesen R, Kolb HJ, et al. Evaluation of C-reaktive Protein, interleukin-6, and procalcitonin levels in allogeneic hematopoetic stem cell recipients. Eur J Haematol. 2006;76:93–101.

    Article  CAS  PubMed  Google Scholar 

  32. Haas P, Ihorst G, Schnitzler S, Wäsch R, Marks R, Bertz H, et al. NT-pro-BNP: not the prognostic all-rounder in elderly patients undergoing allogeneic stem cell transplantation. Ann Hematol. 2012;91:1929–35.

    Article  CAS  PubMed  Google Scholar 

  33. Roziakova L, Bojtarova E, Mistrik M, Dubrava J, Gergel J, Lenkova N, et al. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoetic stem cell transplantation. J Exp Clin Cancer Res. 2012;31:13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Zaucha-Prazmo A, Sadurska E, Drabko K, Kowalczyk J. Can we find a good biochemical marker of early cardiotoxicity in children treated with heamatopoietic stem cell transplantation? Contemp Oncol. 2016;20:220–4.

    CAS  Google Scholar 

  35. Hambach L, Eder M, Dammann E, Schrauder A, Sykora KW, Dieterich C, et al. Diagnostic value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation. Haematologica. 2002;87:643–51.

    CAS  PubMed  Google Scholar 

  36. Lefebvre A, Kural-Menasche A, Darmon M, Thiery G, Feugeas J, Schlemmer B, et al. Use of N-terminal pro-brain natriuretic peptide to detect cardiac origin in critically ill cancer patients with acute respiratory failure. Intensive Care Med. 2008;34:833–9.

    Article  CAS  PubMed  Google Scholar 

  37. Cheng GS, Campbell AP, Xie H, Stednick Z, Callais C, Leisenring WM. Correlation and Agreement of handheld spirometry with laboratory spirometry in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2016;22:925–31.

    Article  PubMed  Google Scholar 

  38. Nakamae M, Yamashita M, Koh H, Nishimoto M, Hayashi Y, Nakane T. Lung function core including a parameter of small airway disease as a highly predictive indicator of survival after allogeneic hematopoietic cell transplantation. Transplant Int. 2016;29:707–14.

    Article  Google Scholar 

  39. Lee ML, Gail M, Pfeiffer R, Satten G, Cai T, Gandy A. Risk assessment and evaluation of predictions. New York, NY: Springer; 2013.

    Book  Google Scholar 

  40. Moons K, de Groot J, Linnet K, Linnet K, Reitsma J, Bossuyt P. Quantifying the added value of a diagnostic test or marker. Clin Chem. 2012;58:1408–17.

    Article  PubMed  Google Scholar 

  41. Grund B, Sabin C. Analysis of biomarker data: logs, odds ratios and ROC curves. Curr Opin HIV AIDS. 2010;5:473–9.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Pencina MJ, D’Agostino RB, Pencina KM, Jansens AC, Greenland P. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol. 2012;176:473–81.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Brodska H, Drabek T, Malickova K, Kazda A, Vitek A, Zima T, Markova M. Marked increase of procalcitonin after the administration of antithymocyte globulin in patients before hematopoetic stem cell transplantation does not indicate sepsis: a prospective study. Crit Care. 2009;13:R37.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Sorror ML, Martin PJ, Storb RF, Bhatia S, Maziarz RT, Pulsipher MA, et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood. 2014;124:287–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Hemmati PG, Terwey TH, le Coutre P, Vuong LG, Massenkeil G, Dörken B, et al. A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants. Eur J Haematol. 2011;86:305–16.

    Article  PubMed  Google Scholar 

  46. Birninger N, Bornhäuser M, Schaich M, Ehninger G, Schetelig J. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk aml patients undergoing allogeneic transplantation—investigation of potential limitations of the index. Biol Blood Marrow Transplant. 2011;17:1822–32.

    Article  PubMed  Google Scholar 

  47. Sato M, Nakasone H, Oshima K, Ishihara Y, Wada H, Sakamoto K. Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCT. Bone Marrow Transplant. 2013;48:698–702.

    Article  CAS  PubMed  Google Scholar 

  48. Schots R, Kaufman L, Van Riet I, Lacor P, Trullemans F, De Waale M, et al. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant. 1998;22:79–85.

    Article  CAS  PubMed  Google Scholar 

  49. Aki SZ, Suyani E, Bildaci Y, Cakar M, Baysal N, Sucak GT. Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation. Clin Transplant. 2012;26:E513–E521.

    Article  CAS  PubMed  Google Scholar 

  50. Kim DH, Sohn SK, Baek JH, Kim JG, Lee Ny, Won D, et al. Clinical significance of platelet count at day + 60 after allogeneic peripheral blood stem cell transplantation. J Korean Med Sci. 2006;21:46–51.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Bruno B, Gooley T, Sullivan KM, Davis C, Bensinger W, Storb R, et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:154–62.

    Article  CAS  PubMed  Google Scholar 

  52. Estcourt LJ, Stanworth SJ, Doree C, Hopewell S, Trivella M, Murphy MF. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev. 2015;11:CD010983.

    Google Scholar 

  53. Stanworth SJ,Estcourt LJ,Powter G,Kahan BC,Dyer C,Choo L, et al.TOPPS Investigators A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013;368:1771–80.

    Article  CAS  PubMed  Google Scholar 

  54. Pihusch M, Bleeding complications after hematopoietic stem cell transplantation. Semin Hematol. 2004;41:93–100.

    Article  PubMed  Google Scholar 

  55. Nagasawa M, Ohkawa T, Endo A, Mitsuiki N, Ono T, Aoki Y, et al. Early coagulation disorder after allogeneic stem cell transplantation is a strong prognostic factor for transplantation-related mortality, and intervention with recombinant human thrombomodulin improves the outcome: a single-center experience. Int J Hematol. 2013;98:533–42.

    Article  CAS  PubMed  Google Scholar 

  56. Yue H, Li Z, Aining S, Lu X, Hu L, Zhou L, et al. Alterations of hemostatic parameters in the early development of allogeneic hematopoietic stem cell transplantation-related complications. Ann Hematol. 2011;90:1201–8.

    Article  Google Scholar 

  57. Weber M, Kröger N, Langer F, Hansen A, Zabelina T, Eifrig B, et al. Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31:817–22.

    Article  CAS  PubMed  Google Scholar 

  58. Nevo S, Vogelsang GB. Acute bleeding complications in patients after bone marrow transplantation. Curr Opin Hematol. 2001;8:319–25.

    Article  CAS  PubMed  Google Scholar 

  59. Ishihara T, Nogami K, Matsumoto T, Nomura A, Takeshita Y, Ochi S, et al. Potentially life threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leucemia after hematopoietic stem-cell transplantation. J Hematol. 2017;106:126–34.

    Google Scholar 

  60. Smith LJ, Katzenstein AL. Pathogenesis of massive pulmonary hemorrhage in acute leukemia. Arch Intern Med. 1982;142:2149–52.

    Article  CAS  PubMed  Google Scholar 

  61. Srivasta A, Gottlieb D, Bradstock KF. Diffuse alveolar haemorrhage associated with microangiopathy after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:863–7.

    Google Scholar 

  62. Asakura H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K, et al. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2016;14:42.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Aota T, Wada H, Fujimoto N, Sugimoto K, Yamashita Y, Matsumoto T, et al. The valuable diagnosis of DIC and pre-DIC and prediction of a poor outcome by the evaluation of diagnostic criteria for DIC in patients with hematopoietic injury established by the Japanese Society of Thrombosis and Hemostasis. Thromb Res. 2016;147:80–84.

    Article  CAS  PubMed  Google Scholar 

  64. Dhingra R, Gona P, Wang TJ, Fox CS, D’Agostino RB, Vasan RS. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler Thromb Vasc Biol. 2010;30:1855–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Samsky MD, Patel CB, DeWald TA, Smith AD, Felker GM, Rogers J, et al. Cardiohepatic interactions in heart failure: an overview and clinical implications. J Am Coll Cardiol. 2013;61:2397–405.

    Article  PubMed  Google Scholar 

  66. Maisel A, Mueller C, Neath SX, Christenson RH, Morgenthaler NG, McCord J, et al. Copeptin helps in the early detection of patients with acute myocardial infarction. J Am Coll Cardiol. 2013;62:150–60.

    Article  CAS  PubMed  Google Scholar 

  67. Kerbert AJC, Verspaget HW, Navarro ÀA, Jalan R, Solà E, Benten D, et al. CANONIC Study Investigators of the EASL-CLIF Consortium Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. Crit Care. 2017;21:321.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Mohamed GB, Saed MA, Abdelhakeem AA, Salah K, Saed AM. Predictive value of copeptin as a severity marker of community-acquired pneumonia. Electron Physician. 2017;9:4880–5.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro B-type natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 2008;52:266–72.

    Article  CAS  PubMed  Google Scholar 

  70. Zamorano J, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37:2768–801.

    Article  PubMed  Google Scholar 

  71. Halligan S, Altman DG, Malletts S. Disadvantages of using the area under the receiver operating characteristic curve to assess imaging tests: a discussion and proposal for an alternative approach. Eur Radiol. 2015;25:932–9.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Leening MJ, Vedder MM, Witteman JC, Pencina MJ, Steyerberg EW. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician’s guide. Ann Intern Med. 2014;160:122–31.

    Article  PubMed  Google Scholar 

  73. Mühlenbruch K, Heraclides A, Steyerberg EW, Joost HG, Boeing H, Schulze MB. Assessing improvement in disease prediction using net reclassification improvement: impact of risk cut-offs and number of risk categories. Eur J Epidemiol. 2013;28:25–33.

    Article  PubMed  Google Scholar 

  74. Pickering JW, Endre ZH. New metrics for assessing diagnostic potential of candidate biomarkers. Clin J Am Soc Nephrol. 2012;7:1355–64.

    Article  PubMed  Google Scholar 

  75. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem. 2008;54:17–23.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We express our gratitude to Christiane Gläser for the management at the transplantation unit, Robert Bergmann for the management of the blood samples, Luisa Janik and Sonia Pohlmann for the spirometries and Kathrin Dehne for IT-support.

Funding

The study was supported by a grant from Novartis Switzerland.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. D. Braun.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Braun, S.D., Kuhn, M., Bergmann, S. et al. Net reclassification improvement with serial biomarkers and bed-sided spirometry to early predict the need of organ support during the early post-transplantation in-hospital stay in allogeneic HCT recipients. Bone Marrow Transplant 54, 265–274 (2019). https://doi.org/10.1038/s41409-018-0258-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0258-6

Search

Quick links